HIV包膜蛋白DNA电穿孔疫苗可诱导T细胞与记忆B细胞应答但血清抗体水平较低,可经重组蛋白加强
HVTN 304为首次人体1期试验,在20名无HIV感染者中评估IL-12佐剂DNA疫苗经皮内自适应电穿孔递送的安全性及免疫原性。方案未诱导血清自体中和抗体,但诱导Env结合抗体、CD4+与CD8+ T细胞应答,重组蛋白加强可提升抗体水平。
要点
- DNA疫苗经皮内电穿孔递送安全,可诱导Env特异性CD4+和CD8+ T细胞应答
- 单独DNA未诱导血清中和抗体,结合抗体主要靶向Env基部
- 重组蛋白Trimer 4571加强可提升结合抗体水平并扩大表位覆盖
核心结论
- DNA疫苗联合密切相关的异源重组蛋白加强,可启动B细胞和CD8+ T细胞应答而不诱导高滴度血清抗体,或可作为HIV-1疫苗方案迭代测试的又一技术路线。
研究设计与样本
- HVTN 304(NCT05828095)为首次人体1期临床试验,在20名无HIV感染者中评估sD-NLT-AB05 DNA疫苗(IL-12 DNA佐剂)单独或联合Trimer 4571重组蛋白(3M-052-AF/Alum佐剂)加强的安全性及免疫原性。
- DNA载体经皮内自适应电穿孔递送。
主要发现
- 方案未诱导血清自体中和抗体。
- 接受DNA-only者中超过半数诱导Env结合抗体,接受Trimer 4571加强者全部诱导结合抗体,且第二次蛋白加强后抗体 magnitude 增加。
- DNA诱导的抗体主要针对Env基部,部分Trimer蛋白诱导抗体针对Env其他区域及基部。
- 全部参与者检出表达IFN-γ和/或IL-2的Env特异性CD4+ T细胞,CD8+ T细胞检出率最高达75%。
- CD4+ T细胞应答包括表达IL-21的细胞。
临床怎么用
- 该DNA初免-异源蛋白加强策略可在不诱导高滴度血清抗体的情况下启动B细胞和CD8+ T细胞应答,支持将其用于HIV-1疫苗方案的迭代测试。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Broadly neutralizing antibodies against the HIV envelope protein exhibit the potential to prevent HIV-1 acquisition, a concept demonstrated both in non-human primate (NHP) challenge models and in human clinical trials. The use of DNA for vaccination, in combination with IL-12 and delivered via intradermal (ID)-adaptive electroporation (EP), has resulted in excellent cellular and humoral immunogenicity. HVTN 304 (NCT05828095) is a first-in-human, phase 1 clinical trial that evaluated the safety and immunogenicity of a novel vaccination regimen of a synthetic DNA-encoded stabilized HIV-1 Env native-like trimer (sD-NLT-AB05) adjuvanted with IL-12 DNA, either alone or in combination with a recombinant protein HIV-1 Env (Trimer 4571) adjuvanted with 3M-052-AF/Alum as a boost, in 20 participants without HIV. The DNA vectors were delivered via ID EP. The regimen did not induce autologous neutralizing antibodies in serum. Binding antibodies to Env were induced in over half of the participants receiving DNA only and in all participants who received the Trimer 4571 boost; the magnitude was increased by the second protein boost. The DNA-induced antibodies were primarily directed to the Env base; some Trimer protein-induced antibodies were directed to other regions of Env and the base. Env-specific CD4+ T cells expressing IFN-γ and/or IL-2 were detected in all participants, with CD8+ T cells detected in up to 75% of participants. The CD4+ T cell response included cells expressing IL-21. This study demonstrates that the DNA modality, in combination with a closely related heterologous boost, may be another modality to enable iterative testing of new vaccine regimens for HIV-1, as it primes a B cell response and a CD8+ T cell response without inducing high titers of serum antibody.
引用
- De Rosa SC, Gravett RM, Hahn WO, et al. DNA electroporation of HIV Env elicits robust T cell responses and memory B cell responses with muted serum antibody levels that can be boosted with recombinant protein. Vaccine. 2026. PMID: 41865485. doi:10.1016/j.vaccine.2026.128487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。